Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.
The Health Disparities Advisory Group is focused on developing resources related to data and formulary and utilization management solutions that can close the gap on disparities in medication use. This advisory group is active from March 2022-February 2023.
The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.
The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group will launch in Q4 2022.
